# EDGAR Filing Document

**Accession Number:** 0001107421
**File Stem:** 0000000000-25-009437
**Filing Date:** 2025-9
**Character Count:** 4149
**Document Hash:** 2e6101331272e5532ae51c1bb0e0fce2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009437.hdr.sgml**: 20260625

**ACCESSION NUMBER**: 0000000000-25-009437

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250902

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alaunos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001107421
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 841475642
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289748

**BUSINESS ADDRESS:**
- **STREET 1:** 501 E LAS OLAS BLVD
- **STREET 2:** SUITE 300
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** (346) 355-4099

**MAIL ADDRESS:**
- **STREET 1:** 501 E LAS OLAS BLVD
- **STREET 2:** SUITE 300
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZIOPHARM ONCOLOGY INC
- **DATE OF NAME CHANGE:** 20050919

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EASYWEB INC
- **DATE OF NAME CHANGE:** 20010213
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-184432

## Text-Extract

```

                                                            September 2, 2025

Holger Weis
Chief Executive Officer
Alaunos Therapeutics, Inc.
501 E. Las Olas Blvd., Suite 300
Fort Lauderdale, FL 33301

       Re: Alaunos Therapeutics, Inc.
           Registration Statement on Form S-3
           Filed August 21, 2025
           File No. 333-289748
Dear Holger Weis:

       We have conducted a limited review of your registration statement and
have the
following comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-3 filed August 21, 2025
General

1.     We note that the registration statement includes the proposed resale of
common shares
       to be issued pursuant to an equity line financing arrangement with Mast
Hill Fund,
       L.P. Question 139.13 of the Securities Act Sections Compliance and
Disclosure
       Interpretations, available on our website, provides that, in order for
shares to be
       registered on a resale basis under an equity line financing, the resale
registration
       statement must be on a form that the company is eligible to use for a
primary offering.
       Given that the aggregate market value of your common equity held by
non-affiliates
       does not exceed the $75 million threshold set forth in General
Instruction I.B.1 to
       Form S-3, it does not appear that you are eligible to use Form S-3 for a
primary
       offering. Accordingly, please provide us with an analysis supporting
your
 September 2, 2025
Page 2

       determination that the offering may be registered on Form S-3 or amend
your
       registration statement as appropriate.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Jason Drory at 202-551-8342 or Jessica Dickerson at
202-551-8013
with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Scott Doney, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._